A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
You may also be interested in...
The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.
IVD manufacturers look set to be granted up to 18 more months to comply with the EU IVD Regulation very soon.
Despite increased pressures from inflation and dependence on international supply chains, the average cost of generics in Canada is 45% lower than in 11 comparator countries, the CGPA reports.